Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1 billion initiative that was signed into law in June of 2008. The Center's mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community.

Massachusetts Life Sciences Center, established in 2006 and headquartered in United States, North America., specializes in Early Stage Venture, Seed investments across Biotechnology, Health Care, Pharmaceutical, Therapeutics, Life Science, Health Diagnostics, Medical, Genetics, Tutoring, Diabetes. The organization boasts a portfolio of 163 investments, with an average round size of $1.1M and 13 successful exits. Their recent investments include Hepregen, Immunetics, Reflectance Medical, Candel Therapeutics, Joslin Diabetes Center. The highest investment round they participated in was $1.9B. Among their most notable exits are Hepregen and Immunetics. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.